Commission consults pharma on lessons learnt from EU paediatric law
This article was originally published in Scrip
Pharmaceutical companies who believe that the EU Paediatric Regulation has delayed the authorisation of adult medicines and has created unnecessary administrative burden can respond to a European Commission consultation on "lessons learnt" from the legislation.
You may also be interested in...
As companies undergo pharmacovigilance inspections from a growing multitude of regulatory authorities from around the globe, a senior pharmaceutical industry executive discusses how her company has been handling this complex and challenging task.
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.